TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity value of CEUS for tumour recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ECG parameter test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of dose limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Lung Function indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in HbO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in Hbr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective response rate (ORR; complete response + partial response [CR + PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal ideation, plans and attempts
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of PDPH
Endpoint domain: Adverse events/effects
Primary endpoint: severity of PDPH
Endpoint domain: Adverse events/effects
Primary endpoint: PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months
Endpoint domain: Mortality/survival
Primary endpoint: Segment and instent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Any Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With a Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With All Grades of Oral Mucositis (OM)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of small genetic alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients treated for epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of epileptic crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of comorbidity presented by patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf Motor Function Test Short Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Questionnaire 5 (ACQ5) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection and characterization of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Natural Killer (NK) Cell Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalization-associated Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of influenza cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of tissue acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical function scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in occupational satisfaction and balance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in valued activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in personal recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fold changes of differentially-expressed microRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of aspirated thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CO-confirmed 7-day point prevalence abstinence from cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Electroencephalogram (QEEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time of Narcotrend Index (NCI) values ≤ 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection With Chlamydia Trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of ventral hernia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Pressure Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occlusion of access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 6-Minute Walk Test Distance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of dipyridamole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Very Long Chain Fatty Acids (VLCFA) Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of VEGF mRNA expression in tumor biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of VEGFR2 phosphorylation with IHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of RMG-4DCBCT image guidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulation concentration of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulation concentrations of 4 types of lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulation concentrations of 5 minerals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of colorectal cancer (CRC) markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Work Injury Claims During the Study Period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medical Expenditures Related to Work Injury Claims During the Study Period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Missed Work Days Due to Illness or Injury
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Modified Roland-Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Healing of the Study Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Knowledge of evidence-based Psychology
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception of Evidence-based Psychology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Functional Independence Measure (FIM) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evidence of HIV-1 Infection or Death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of long-term care disability
Endpoint domain: Mortality/survival
Primary endpoint: Total Number of Asthma Exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in IgA anti-tissue transglutaminase (anti-tTG) antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in IgA anti-endomysium antibodies (EMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathologic variations in histologic analysis from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial lipaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Patients Achieving an Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional distribution of pulmonary perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygenation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in concentrations of fasting plasma glucose and lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psychomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Covid-19-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Covid-19-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Skin erythema index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measurement of prostate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the prostate cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale - Parent
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nutritional status based on phase angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status based on force measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Initiation of Antiretroviral Therapy within 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility degree of matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with primary dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of Cells Staining Positive for Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of all adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Opioid Consumption Intraop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Consumption Postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side Effects Such as Nausea, Itching, Constipation
Endpoint domain: Adverse events/effects
Primary endpoint: Risk exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intentions to engage in unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Clinical Global Impressions Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total pethidine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One hour pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heel-Rise Endurance Test (HRET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal Attainment Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Migraine Headache Index (MHI) at 1 Year
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Migraine Headache Index (MHI) at 2 Years
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Migraine Headache Index (MHI) at 2.5 Years
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean of total sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Gene mutation detection of BRCA1 and BRCA2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of loop recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in nasal mucosa assessed by rhinoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nasal flow and resistance assessed by rhinomanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy value of pistachios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of effector memory immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in frequency of central memory immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in frequency of regulatory immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in capacity to climb stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mGlu5 receptor binding assessed by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry/radiation safety assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Test-retest precision of PET images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients showing covert hepatic encephalopathy reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: health-related quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death-censored Graft Loss or Greater Than 50% Reduction in eGFR
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of lung ultrasound in optimizing PEEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Latency to Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of time difference in Stroop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma (AUC0-tz) for Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma (AUC0-tz) for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma (AUC0-72) for Linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary Reflex Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forced Oscillation Technique (FOT) Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acquisition of Staphylococcus aureus nasal colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Change in calcium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: optimal biologic dose (OBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrence of bipolar disorder
Endpoint domain: Mortality/survival
Primary endpoint: Numbers of Participants With Heel Pressure Sores
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NFC Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of anxiety/depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Acute Rejection or Antibody Mediated Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Diameter of retinal vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic vessel reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: gene expression in amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-Life (t1/2) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent First-order Terminal Elimination Half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20/50/70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACTIT Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Disease progression measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator Global Assessment (IGA) Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QRISK3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percentage of Cells Staining Positive for Annexin V Binding in Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Chemiluminescence (AUC) of Neutrophil Reactive Species Production Using Formyl-Methionyl-Leucyl-Phenylalanine (fMLP) Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Neutrophils Positive for Dihydrorhodamine-123 (DHR) Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of palbociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change in pocket probing depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Degree of inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity patterns in the amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Who Experienced Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lesion stenosis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean clearances of clindamycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration curves of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic Nerve Sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: treatment failure within the first 72 hours of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic response including radiographic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of diarrhea grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of women continuing to use initial contraceptive method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluation of prescribing protocol adherence
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic evidence of fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Asthma severity and level of control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Dummett oral pigmentation index (DOPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival brightness (ΔL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological mean area fraction of melanosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Seroresponse to the Spike (S) Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Local Solicited Adverse Events
Endpoint domain: Adverse events/effects